---
annotations:
- type: Pathway Ontology
  value: signaling pathway
- type: Pathway Ontology
  value: kinase mediated signaling pathway
authors:
- ReactomeTeam
- Anwesha
- Ryanmiller
description: The RAS-RAF-MEK-ERK pathway regulates processes such as proliferation,
  differentiation, survival, senescence and cell motility in response to growth factors,
  hormones and cytokines, among others. Binding of these stimuli to receptors in the
  plasma membrane promotes the GEF-mediated activation of RAS at the plasma membrane
  and initiates the three-tiered kinase cascade of the conventional MAPK cascades.  GTP-bound
  RAS recruits RAF (the MAPK kinase kinase), and promotes its dimerization and activation
  (reviewed in Cseh et al, 2014; Roskoski, 2010; McKay and Morrison, 2007; Wellbrock
  et al, 2004).  Activated RAF phosphorylates the MAPK kinase proteins MEK1 and MEK2
  (also known as MAP2K1 and MAP2K2), which in turn phophorylate the proline-directed
  kinases ERK1 and 2 (also known as MAPK3 and MAPK1) (reviewed in Roskoski, 2012a,
  b; Kryiakis and Avruch, 2012).  Activated ERK proteins may undergo dimerization
  and have identified targets in both the nucleus and the cytosol; consistent with
  this, a proportion of activated ERK protein relocalizes to the nucleus in response
  to stimuli (reviewed in Roskoski 2012b; Turjanski et al, 2007; Plotnikov et al,
  2010; Cargnello et al, 2011).  Although initially seen as a linear cascade originating
  at the plasma membrane and culminating in the nucleus, the RAS/RAF MAPK cascade
  is now also known to be activated from various intracellular location.  Temporal
  and spatial specificity of the cascade is achieved in part through the interaction
  of pathway components with numerous scaffolding proteins (reviewed in McKay and
  Morrison, 2007; Brown and Sacks, 2009). <br> The importance of the RAS/RAF MAPK
  cascade is highlighted by the fact that components of this pathway are mutated with
  high frequency in a large number of human cancers.  Activating mutations in RAS
  are found in approximately one third of human cancers, while ~8% of tumors express
  an activated form of BRAF (Roberts and Der, 2007; Davies et al, 2002; Cantwell-Dorris
  et al, 2011).  View original pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=5673001
  Reactome].
last-edited: 2021-01-25
organisms:
- Homo sapiens
redirect_from:
- /index.php/Pathway:WP2735
- /instance/WP2735
schema-jsonld:
- '@context': https://schema.org/
  '@id': https://wikipathways.github.io/pathways/WP2735.html
  '@type': Dataset
  creator:
    '@type': Organization
    name: WikiPathways
  description: The RAS-RAF-MEK-ERK pathway regulates processes such as proliferation,
    differentiation, survival, senescence and cell motility in response to growth
    factors, hormones and cytokines, among others. Binding of these stimuli to receptors
    in the plasma membrane promotes the GEF-mediated activation of RAS at the plasma
    membrane and initiates the three-tiered kinase cascade of the conventional MAPK
    cascades.  GTP-bound RAS recruits RAF (the MAPK kinase kinase), and promotes its
    dimerization and activation (reviewed in Cseh et al, 2014; Roskoski, 2010; McKay
    and Morrison, 2007; Wellbrock et al, 2004).  Activated RAF phosphorylates the
    MAPK kinase proteins MEK1 and MEK2 (also known as MAP2K1 and MAP2K2), which in
    turn phophorylate the proline-directed kinases ERK1 and 2 (also known as MAPK3
    and MAPK1) (reviewed in Roskoski, 2012a, b; Kryiakis and Avruch, 2012).  Activated
    ERK proteins may undergo dimerization and have identified targets in both the
    nucleus and the cytosol; consistent with this, a proportion of activated ERK protein
    relocalizes to the nucleus in response to stimuli (reviewed in Roskoski 2012b;
    Turjanski et al, 2007; Plotnikov et al, 2010; Cargnello et al, 2011).  Although
    initially seen as a linear cascade originating at the plasma membrane and culminating
    in the nucleus, the RAS/RAF MAPK cascade is now also known to be activated from
    various intracellular location.  Temporal and spatial specificity of the cascade
    is achieved in part through the interaction of pathway components with numerous
    scaffolding proteins (reviewed in McKay and Morrison, 2007; Brown and Sacks, 2009).
    <br> The importance of the RAS/RAF MAPK cascade is highlighted by the fact that
    components of this pathway are mutated with high frequency in a large number of
    human cancers.  Activating mutations in RAS are found in approximately one third
    of human cancers, while ~8% of tumors express an activated form of BRAF (Roberts
    and Der, 2007; Davies et al, 2002; Cantwell-Dorris et al, 2011).  View original
    pathway at [http://www.reactome.org/PathwayBrowser/#DIAGRAM=5673001 Reactome].
  keywords:
  - 'p-T184-RASGRP1 '
  - and dimers:PEA15
  - 'PSMD6 '
  - 'PSMB9 '
  - 'AREG(101-187) '
  - Signaling by FGFR4
  - 'GFRA3 '
  - 'p-S218,S222-MAP2K1 '
  - complexes
  - NCAM signaling for
  - 'p-7Y-KIT '
  - Neurotransmitter
  - 'MARK3 '
  - MAP2K:p-2T
  - activated
  - 'Ca2+ '
  - 'PPP2R5A '
  - inhibitors
  - 'HGF(495-728) '
  - 'p-Y194,Y195,Y272-SHC1-3 '
  - MAP2Ks:p-T,Y MAPKs
  - In cells expressing both ERBB2 and EGFR, EGF stimulation of EGFR leads to formation
    of both ERBB2:EGFR heterodimers (Wada et al. 1990, Karunagaran et al. 1996) and
    EGFR homodimers. Heterodimers of ERBB2 and EGFR trans-autophosphorylate on twelve
    tyrosine residues, six in the C-tail of EGFR and six in the C-tail of ERBB2 -
    Y1023, Y1139, Y1196, Y1221, Y1222 and Y1248 (Margolis et al. 1989, Hazan et al.
    1990,Walton et  al. 1990, Helin et al. 1991, Ricci et al. 1995, Pinkas-Kramarski
    1996). Phosphorylated tyrosine residues in the C-tail of EGFR and ERBB2 serve
    as docking sites for downstream signaling molecules. Three key signaling pathways
    activated by ERBB2:EGFR heterodimers are RAF/MAP kinase cascade, PI3K-induced
    AKT signaling, and signaling by phospholipase C gamma (PLCG1). Downregulation
    of EGFR signaling is mediated by ubiquitin ligase CBL, and is shown under Signaling
    by EGFR.<br><br>
  - 'IL2 '
  - 'Activated FGFR2b homodimer bound to FGF '
  - 'NF1(2-2839) '
  - ADP
  - 'RASA3 '
  - 'Phosphorylated ERBB2:ERBB4cyt1 heterodimers '
  - 'APBB1IP '
  - 'IL2RG '
  - Signaling by FGFR2
  - 'BRAF K601E '
  - 'MyrG-p-Y419-SRC '
  - Interleukin-3,
  - 'UBB(77-152) '
  - 'p-Y1234,Y1235,Y1349,Y1356-MET '
  - '''activator'''
  - MAPK:single
  - 'p-Y-IRS2 '
  - 'PEBP1 '
  - '"receiver" RAF/KSR1'
  - 'ARRB1 '
  - 'PDGFA-2 '
  - 'PPP2R5E '
  - 'FGF19 '
  - MAP3K11
  - p21RAS:GTP:activated
  - 'p-T183,Y185-MAPK12 '
  - 'PSMB4 '
  - 'PSMB1 '
  - 'p-5Y-FGFR4 '
  - 'PSMD2 '
  - 'p-S311,S406 KSR1 '
  - 'UBB(1-76) '
  - 'MAP2K1 F53S '
  - p-S459
  - 'p-6Y,Y1112-ERBB2 '
  - 'BRAF S467A '
  - 'RASAL3 '
  - homo/heterodimer:PEBP1
  - 'MAPK1 '
  - 'ARRB2 '
  - 'PDGFB (82-190) '
  - ATP
  - 'RAP1B '
  - 'PSMC3 '
  - dimer
  - BRAF inhibitors
  - 'p-S259,S621-RAF1 '
  - 'RGL1 '
  - 'p-Y239,Y240,Y317-SHC1-2 '
  - 'SPTB '
  - 'SPTBN5 '
  - In cells expressing ERBB2 and ERBB3, ERBB3 activated by neuregulin NRG1 or NRG2
    binding (Tzahar et al. 1994) forms a heterodimer with ERBB2 (Pinkas-Kramarski
    et al. 1996, Citri et al. 2004). ERBB3 is the only EGFR family member with no
    kinase activity, and can only function in heterodimers, with ERBB2 being its preferred
    heterodimerization partner. After heterodimerization, ERBB2 phosphorylates ten
    tyrosine residues in the C-tail of ERBB3, Y1054, Y1197, Y1199, Y1222, Y1224, Y1260,
    Y1262, Y1276, Y1289 and Y1328 (Prigent et al. 1994, Pinkas-Kramarski et al. 1996,
    Vijapurkar et al. 2003, Li et al. 2007) that subsequently serve as docking sites
    for downstream signaling molecules, resulting in activation of PI3K-induced AKT
    signaling and RAF/MAP kinase cascade. Signaling by ERBB3 is downregulated by the
    action of RNF41 ubiquitin ligase, also known as NRDP1. <br><br>
  - 'SPTAN1 '
  - 'FGA '
  - GM-CSF signaling
  - 'IL2RA '
  - 'UBC(533-608) '
  - HRAS:GTP
  - RAS:GTP:homo/heterodimerized RAF complex
  - p-S338,Y341,T491,S494,S621 RAF1
  - 'p-S445,T599,S602,S729 BRAF '
  - 'DUSP8 '
  - 'PAQR3 '
  - 'IQGAP1 '
  - 'p-Y-IRS1 '
  - 'p-5Y-LAT-2 '
  - Signaling by Insulin
  - BRAP
  - 'p-Y341,T491,S494,S621 RAF1 '
  - S-GCC
  - 'p-Y317-SHC1-2 '
  - 'Activated FGFR2c homodimer bound to FGF '
  - 'GalNAc-T178-FGF23(25-251) '
  - PTPN7:p-T-MAPK
  - 'MAP2K1 Q56P '
  - PTPN3:p-T183,Y185-MAPK12
  - 'p-T287-CAMK2B '
  - BRAF mutants
  - 'BRAF G534R '
  - p21 RAS:GTP:ub-BRAP
  - neurite out-growth
  - 'CAMK2B '
  - 'MAP2K1 Y130C '
  - Insulin-like Growth
  - 'DUSP9 '
  - 'CALM1 '
  - 'CNKSR1 '
  - 'CSK '
  - variant dimer
  - Interleukin-5 and
  - 'MAP2K1 F53Y '
  - 'MAP2K1 D67N '
  - GDP
  - 'D-Ser '
  - PP2A
  - 'L-Glu '
  - 'PSMD8 '
  - RAF:scaffold:MAP2K:MAPK complex
  - 'KITLG-1(26-190) '
  - 'High affinity binding complex dimers of cytokine receptors using Bc, inactive
    JAK2, p-(Y593,628)-Bc:p(427,349,350)-SHC1 '
  - p21 RAS:GTP
  - 'MAP2K2 F57C '
  - 'FGF5-1 '
  - Signaling by FGFR1
  - 'SPRED1 '
  - Factor 1 Receptor
  - 'PSMA5 '
  - 'PSMD1 '
  - 'FGF8-1 '
  - PPP5C
  - Signaling by NTRK1
  - 'EPGN(23-154) '
  - 'SYNGAP1 '
  - 'FGF2(10-155) '
  - 'PSMC4 '
  - 'SPTA1 '
  - 'p-12Y-PDGFRB '
  - interactions at the
  - 'Neuregulins '
  - 'p-Y1172,Y1226-ERBB4 JM-A CYT-2 isoform '
  - 'FGF10 '
  - 'SPRED3 '
  - 'UBC(153-228) '
  - 'p-S338,Y341,T491,S494,S621 RAF1 '
  - HRAS:GTP:RAL GDS
  - 'PSMC2 '
  - 'MAP2K1 V60E '
  - 'FGF4 '
  - 'p-Y364,Y418,Y536-IL2RB '
  - 'PSPN '
  - RAS GAPs
  - 'LAMTOR2 '
  - MAP2K:MAPK:single
  - RAS:GTP:activated
  - 'BRAF K499E '
  - 'DUSP6 '
  - 'BRAF L485F '
  - MAP2K
  - kinases
  - Signaling by EGFR
  - 'MAP2K1 K57T '
  - KSR1:MARK3
  - MAP2K1/2 inhibitors
  - 'S-Farn-Me-PalmS KRAS4A '
  - 'GDP '
  - 'PSMA6 '
  - SPRED dimer:NF1
  - PEBP1
  - WDR83:LAMTOR2:LAMTOR3
  - 'EREG(60-108) '
  - 'PPP2R5B '
  - Signaling by FGFR3
  - 'GTP '
  - 'FGF20 '
  - 'SCH772984 '
  - 'FGF23(25-251) '
  - Other interleukin
  - 'GRB2-1 '
  - 'NEFL '
  - 'PSME3 '
  - 'RALGDS '
  - 'TAK-580 '
  - NF1(2-2839)
  - 'p-Y-SHC3 '
  - 'PDGFA-1 '
  - MAPK12
  - 'SHFM1 '
  - 'Autophosphorylated FLT3 '
  - 'p-T202-MAPK3 '
  - YWHAB dimer
  - 'KL-1 '
  - 'MAP2K2 '
  - Signaling by PDGF
  - p-2S MAP2K
  - 'ITGB3 '
  - 'RAPGEF2 '
  - 'p-T185-MAPK1 '
  - 'RASAL2 '
  - 'p-6Y-FRS2 '
  - SPRED dimer
  - BRAP:KSR1:MARK3
  - 'RAF:scaffold:p-2S '
  - 'MAP2K2 Y134C '
  - 'GRIN2B '
  - PHB
  - postsynaptic signal
  - 'RGL2 '
  - Cell Receptor (BCR)
  - 'UBC(609-684) '
  - 'MAP2K1 F53C '
  - 'MAP2K1 F53L '
  - 'SPTBN4 '
  - 'ACTN2 '
  - WDR83:LAMTOR2:LAMTOR3:activated RAF:p-2S MAP2K:p-T,Y MAPK complex
  - 'DLG1 '
  - 'MAP2K1 P124Q '
  - 'SPTBN2 '
  - 'PPP2R1A '
  - 'MAPKs '
  - 'PSME4 '
  - 'IL17RD '
  - 'PSMB7 '
  - MAP2K1 and MAP2K2
  - 'BRAF Q257R '
  - 'p-Y-SHC1 '
  - 'p-S299,S302,T452,T455,S576 ARAF '
  - p-T183,Y185-MAPK12
  - 'p-5Y,S1119-TEK '
  - mutants
  - 'PSMA3 '
  - 'PSMC6 '
  - (FCERI) signaling
  - 'p-T286-CAMK2A '
  - RAS:GTP:'activator'
  - 'GFRA2 '
  - 'RASGRP1 '
  - 'DUSP7 '
  - 'KSR2 '
  - 'CUL3 '
  - Signaling by SCF-KIT
  - 'trametinib '
  - p21 RAS:GDP
  - 'PSMF1 '
  - 'FGF9 '
  - 'p-Y-JAK1 '
  - 'PIK3R2 '
  - 'TGFA(24-98) '
  - p21RAS:GTP:p-S621
  - 'ITGA2B(32-1039) '
  - 'MAP2K1 G128D '
  - 'p-ERBB4cyt1 homodimers '
  - WDR83:LAMTOR2:LAMTOR3:activated RAF:MAP2K:MAPK complex
  - 'p-T287-CAMK2D '
  - vascular wall
  - 'RASGEF1A '
  - p21 RAS:GTP:PI3K
  - 'RPS27A(1-76) '
  - 'BRAF 599dupT '
  - 'Gly '
  - 'p-6Y-FGFR3c '
  - p-T,Y MAPK monomers
  - MAPK2K2 heterodimer
  - Signaling by ERBB4
  - 'p-S621-RAF1 '
  - 'Mg2+ '
  - RAF dimer inhibitors
  - PEA15
  - 'RASGRF2 '
  - MRAS:GTP:SHOC2:PP1
  - 'PSMD5 '
  - 'PSMC1 '
  - 'PTPN3 '
  - 'RASGRF1 '
  - nuclear MAPK DUSPs
  - 'dabrafenib mesylate '
  - signaling
  - 'PSMD3 '
  - 'DLG2 '
  - 'PSMA8 '
  - 'PSMC5 '
  - 'FGG '
  - mechanism MAPK
  - p-S445,T599,S602,S729 BRAF
  - 'p-S445,S729-BRAF '
  - 'UBC(1-76) '
  - 'F-actin '
  - 'HBEGF(63-148) '
  - 'DLG3 '
  - p-2S,T MAP2K1:p-2S
  - 'p-7Y,Y1112-ERBB2 '
  - This pathway describes some of the key interactions that assist in the process
    of platelet and leukocyte interaction with the endothelium, in response to injury.
  - 'FGF6 '
  - Fc epsilon receptor
  - 'PSMD9 '
  - DAP12 interactions
  - SPRED dimer:ub-NF1
  - H2O
  - 'VWF(23-763) '
  - 'KL-2 '
  - 'MyrG,p-Y530-SRC '
  - 'p-6Y-FGFR3b '
  - 'p-8Y-FGFR1c '
  - PTPN7:p-T,Y-MAPK
  - homo/heterodimers
  - 'MAP2K2 C125S '
  - MAP2K:MAPK complex
  - 'PSMB2 '
  - 'PSMA7 '
  - KBTBD7:CUL3:RBX1
  - 'DUSP2 '
  - 'MAP2K1 P124S '
  - dimers
  - p21 RAS:GTP:RAS GAPs
  - BRAF
  - 'PSMB6 '
  - PAQR3
  - 'MAP2K1 C121S '
  - In cells expressing ERBB2 and ERBB4, ligand stimulated ERBB4 can either homodimerize
    or form heterodimers with ERBB2 (Li et al. 2007), resulting in trans-autophosphorylation
    of ERBB2 and ERBB4 on C-tail tyrosine residues that will subsequently serve as
    docking sites for downstream signaling molecules, leading to activation of RAF/MAP
    kinase cascade and, in the case of ERBB4 CYT1 isoforms, PI3K-induced AKT signaling
    (Hazan et al. 1990, Cohen et al. 1996, Li et al. 2007, Kaushansky et al. 2008).
    Signaling by ERBB4 is downregulated by the action of WWP1 and ITCH ubiquitin ligases,
    and is shown under Signaling by ERBB4.
  - 'FGF1 '
  - inactive RAFS:YWHAB
  - 'p-Y427-SHC1 '
  - MAPK inhibitors
  - RAF1
  - 'LAMTOR3 '
  - 'PSMA1 '
  - dual mechanism MAPK
  - 'Phosphorylated ERBB2:ERBB4cyt2 heterodimers '
  - 'PTPRA '
  - 'p-T185,Y187-MAPK1 '
  - 'PSMA4 '
  - 'p-S365,S445,S729 BRAF '
  - 'JAK2 '
  - proteins
  - PTPN3
  - MAP2Ks:MAPKs
  - 'S-Farn-Me-2xPalmS HRAS '
  - 'EGF-like ligands '
  - 'PSMB8 '
  - 'GFRA1 '
  - 'p-Y349,Y350-SHC1 '
  - 'cobimetinib '
  - 'p-6Y-EGFR '
  - Interleukin-2 family
  - 'DUSP10 '
  - 'TLN1 '
  - 'DUSP1 '
  - 'p-8Y-FGFR1b '
  - 'BRAF V600E V47_D380del '
  - RAF:scaffold:p-2S
  - 'p-S576 ARAF '
  - 'WDR83 '
  - MAP2K:MAPK:dual
  - 'MAP2K2 V35M '
  - Ub
  - 'GRIN2D '
  - 'PTPN7 '
  - 'PPP2R1B '
  - 'RBX1 '
  - 'PSMD4 '
  - 'S-Farn-Me KRAS4B '
  - 'UBC(77-152) '
  - 'SHOC2 '
  - 'PDGFB(82-241) '
  - 'p-T133-RASGRP3 '
  - 'MAP2K1 P124L '
  - receptor
  - 'p-S,218, S222,T292 MAP2K1 '
  - 'UBC(229-304) '
  - 'JAK3 '
  - 'p-6Y-PTK2 '
  - ERBB2 becomes activated by forming a heterodimer with another ligand-activated
    EGFR family member, either EGFR, ERBB3 or ERBB4, which is accompanied by dissociation
    of chaperoning proteins HSP90 and CDC37 (Citri et al. 2004), as well as ERBB2IP
    (Borg et al. 2000) from ERBB2. ERBB2 heterodimers function to promote cell proliferation,
    cell survival and differentiation, depending on the cellular context. ERBB2 can
    also be activated by homodimerization when it is overexpressed, in cancer for
    example. <br><br>
  - Signaling by Type 1
  - 'PSMB11 '
  - 'PSMB5 '
  - 'DUSP16 '
  - 'ANGPT1 '
  - MAPKs
  - 'p-11Y-PDGFRA '
  - 'FN1(32-2386) '
  - 'PSMD12 '
  - dephosphorylated
  - 'SPRED2 '
  - (IGF1R)
  - 'HS '
  - activated RAF
  - 'PPP1CC '
  - 'KLB '
  - 'MAP2K1 E44_E57del '
  - IL17RD
  - p-T,Y MAPK dimers
  - p21 RAS:GTP:BRAP
  - 'DAB2IP '
  - 'V600E BRAF V169_D380del '
  - 'p-Y420-FYN '
  - 'DAG '
  - 'EGF '
  - 'MAP2K1 E203K '
  - 'YWHAB '
  - 'p-T202,Y204-MAPK3 '
  - 'UBA52(1-76) '
  - 'PIK3CB '
  - 'BRAF V600E V47_M438del '
  - 'MAP2K2 N126D '
  - 'CNKSR2 '
  - 'GRIN1 '
  - 'ARTN '
  - RAF:YWHAB dimer
  - 'DLG4 '
  - PTPN7
  - homo/heterodimer
  - (TRKA)
  - 'PSME1 '
  - 'ub-BRAP '
  - 'PSMD11 '
  - 'Autophosphorylated p-Y877-ERBB2 heterodimers '
  - 'RASAL1 '
  - 'BRAF V600E '
  - 'p-5Y-RET '
  - 'MAP2K1 D67Y '
  - 'p-5Y-FRS3 '
  - 'PEA15 '
  - 'ub-NF1(2-2839) '
  - 'S-GGC MRAS '
  - 'VCL '
  - 'PPP2CA '
  - BRAF inhibitors:high
  - RAS processing
  - 'PSMA2 '
  - 'FGF16 '
  - Signaling by the B
  - 'RASGRP4 '
  - S-Farn-Me_2xPalmS
  - 'BRAF V600E  V169_M438del '
  - 'p-S311 KSR1 '
  - 'RAP1A '
  - 'UBC(305-380) '
  - 'MAP2K1 K57N '
  - 'PSMD14 '
  - high kinase activity
  - 'MAP2K1 '
  - 'p-2S MAP2K homo/heterodimers '
  - 'PSMD13 '
  - p-S311 KSR1:MARK3
  - dual mechanism
  - p21
  - PAQR3:inactive RAFs
  - 'PSME2 '
  - mechanism MAP2K
  - 'CAMK2G '
  - 'CAMK2D '
  - transmission
  - 'UBC(381-456) '
  - 'RANBP9 '
  - 'FGF3 '
  - RAL GDS proteins
  - p21RAS:GTP:homo/heterodimerized RAF complex:RAF dimer inhibitors
  - 'p-Y349,Y350,Y427-SHC1 '
  - 'PPP1CB '
  - 'p-Y-SHC2 '
  - RAF:scaffold:MAP2K:MAPK complex:dual mechanism MAP2K inhibitors
  - 'p-T287-CAMK2G '
  - MAPK monomers and
  - RAS GEFs
  - 'NCAM1 '
  - 'FGF18 '
  - 'CAMK2A '
  - 'BRAF G469A '
  - 'HGF(32-494) '
  - 'PIK3CA '
  - 26S proteasome
  - RAF activating
  - 'PI(4,5)P2 '
  - 'FGB '
  - kinase activity
  - 'ulixertinib '
  - p-S311,S406
  - KSR1:MARK3:YWHAB
  - S-Farn-Me-2xPalmS
  - PI3K
  - RAF
  - 'Mn2+ '
  - 'SPTBN1 '
  - 'PSMB10 '
  - p-S311
  - hyperphosphorylated
  - 'p-S311,Y552 KSR1 '
  - Signaling by ERBB2
  - 'p-S214,S576 ARAF '
  - 'NRTN '
  - 'MAP2K1 F53V '
  - 'FGF22 '
  - 'PPP2R5D '
  - 'KSR1 '
  - and dimers
  - 'DUSP4 '
  - 'GDNF '
  - 'PIK3R1 '
  - 'S-Farn-Me PalmS NRAS '
  - 'RGL3 '
  - 'MAP2K1 G128V '
  - 'p-S459 PTPN3 '
  - 'RASA1 '
  - receptors and
  - IL17RD:p-2S
  - 'PSMB3 '
  - Pi
  - 'MAP2K2 P128Q '
  - 'MAP2K2 L46F '
  - variants
  - 'GFRA4 '
  - 'BRAF K601N '
  - 'BRAP '
  - 'PPP2R5C '
  - 'UBC(457-532) '
  - 'BTC(32-111) '
  - MAP2K:p-2T MAPK
  - 'SOS1 '
  - 'KBTBD7 '
  - 'DUSP5 '
  - 'FLT3LG '
  - RAF/MAPK scaffolds
  - inactive RAFs:YWHAB
  - cytosolic MAPK DUSPs
  - 'MAPK3 '
  - 'FGF17-1 '
  - 'PPP2CB '
  - 'p-T,Y MAPK dimers '
  - 'LRRC7 '
  - V600E BRAF splice
  - Endothelial cells are tightly connected through various proteins, which regulate
    the organization of the junctional complex and bind to cytoskeletal proteins or
    cytoplasmic interaction partners that allow the transfer of intracellular signals.
    An important role for these junctional proteins in governing the transendothelial
    migration of leukocytes under normal or inflammatory conditions has been established.<p>
  - GTP
  - 'RASA4 '
  - p-2S MAP2K1:p-2S
  - 'PSMD7 '
  - p-T,Y MAPKs
  - complex
  - 'RASA2 '
  - inactive RAFs
  - 'p-6Y-ERBB2 heterodimers '
  - 'p-S222,S226-MAP2K2 '
  - single mechanism
  - Cell surface
  - 'UBB(153-228) '
  - 'PSMD10 '
  - p21RAS:GTP:dephosphorylated RAF1 homo/heterodimer
  - 'p-T,Y MAPKs '
  license: CC0
  name: RAF/MAP kinase cascade
seo: CreativeWork
title: RAF/MAP kinase cascade
wpid: WP2735
---